Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lifeline for kids with severe epilepsy: drug access extended

NCT ID NCT03778424

AVAILABLE Disease control Sponsor: Eisai Inc. Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This program offers continued access to rufinamide for children with Lennox-Gastaut syndrome, a severe form of epilepsy, who completed a previous study. The goal is to keep providing the medication until it becomes commercially available in Poland. Only children who were already taking rufinamide in the earlier study can join.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
rufinamide
What this could lead to
If successful, this program ensures children with hard-to-control seizures can keep taking rufinamide without interruption until it is commercially available.
What could go wrong
This is an access program, not a new test of effectiveness. It only includes children who already tolerated the drug, so results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LENNOX GASTAUT SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain disorder epilepsy Lennox-Gastaut syndrome visual epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LENNOX GASTAUT SYNDROME

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Generała Tadeusza Kościuszki 52

    AVAILABLE

    Kielce, Poland

  • Szpital Kliniczny im. Heliodora Święcickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu

    AVAILABLE

    Poznan, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.